Literature DB >> 17105585

Clinical significance of HLA DRB103-DRB104 in type 1 autoimmune hepatitis.

Aldo J Montano-Loza1, Herschel A Carpenter, Albert J Czaja.   

Abstract

BACKGROUND: HLA DRB1*03-DRB1*04 combines both susceptibility factors for type-1 autoimmune hepatitis. AIMS: Determine whether this phenotype is a risk factor for autoimmune hepatitis in white North American patients, assess its associations with clinical features and treatment outcome, and determine whether alleles within this phenotype affect prognosis.
METHODS: One hundred and ninety-eight patients with type 1 autoimmune hepatitis and 102 normal adults were evaluated. HLA typing was performed by DNA-based techniques.
RESULTS: Twenty-eight patients had HLA DRB1*03-DRB1*04, and the frequency was higher than in normal subjects (14% vs 4%, OR 4.0%, 95% CI 1.4-11.8, P = 0.01). Patients with DRB1*03-DRB1*04 relapsed less frequently than patients with DRB1*03 (1.3 +/- 0.3 vs 2.1 +/- 0.2, P = 0.04), but they otherwise had outcomes similar to patients with other phenotypes. Patients with DRB1*03-DRB1*04 who had 3-4 alleles encoding lysine at position DRbeta71 within the class II molecule of the major histocompatibility complex developed cirrhosis more commonly (75% vs 9%, P = 0.05) and had a higher frequency of hepatic-related death or liver transplantation (40% vs 0%, P = 0.04) than patients with fewer alleles.
CONCLUSIONS: HLA DRB1*03-DRB1*04 is a risk factor for type-1 autoimmune hepatitis, and its impact on outcome relates to the diversity of DRB1*04 alleles that encode a critical motif.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17105585     DOI: 10.1111/j.1478-3231.2006.01387.x

Source DB:  PubMed          Journal:  Liver Int        ISSN: 1478-3223            Impact factor:   5.828


  8 in total

1.  Autoimmune Hepatitis in Hawai'i.

Authors:  Tanner I Kim; Jaclyn E Kagihara; Naoky C S Tsai; Marina M Roytman
Journal:  Hawaii J Med Public Health       Date:  2015-08

2.  Impact of pretransplant antinuclear antibody and antismooth muscle antibody titers on disease recurrence and graft survival following liver transplantation in autoimmune hepatitis patients.

Authors:  Nader Dbouk; Samir Parekh
Journal:  J Gastroenterol Hepatol       Date:  2013-03       Impact factor: 4.029

Review 3.  Difficult treatment decisions in autoimmune hepatitis.

Authors:  Albert J Czaja
Journal:  World J Gastroenterol       Date:  2010-02-28       Impact factor: 5.742

Review 4.  Clinical features, differential diagnosis and treatment of autoimmune hepatitis in the elderly.

Authors:  Albert J Czaja
Journal:  Drugs Aging       Date:  2008       Impact factor: 3.923

Review 5.  Auto immune hepatitis.

Authors:  Nicole Mf van Gerven; Ynto S de Boer; Chris Jj Mulder; Carin Mj van Nieuwkerk; Gerd Bouma
Journal:  World J Gastroenterol       Date:  2016-05-21       Impact factor: 5.742

6.  Progressive Fibrosis Is Driven by Genetic Predisposition, Allo-immunity, and Inflammation in Pediatric Liver Transplant Recipients.

Authors:  S Varma; J Ambroise; M Komuta; D Latinne; P Baldin; R Reding; F Smets; X Stephenne; E M Sokal
Journal:  EBioMedicine       Date:  2016-06-01       Impact factor: 8.143

Review 7.  Antigen-Specific Immunotherapy for Treatment of Autoimmune Liver Diseases.

Authors:  Naomi Richardson; Sky T H Ng; David C Wraith
Journal:  Front Immunol       Date:  2020-07-21       Impact factor: 7.561

Review 8.  Significance of progressive liver fibrosis in pediatric liver transplants: A review of current evidence.

Authors:  Mathew George; Philippe Paci; Timucin Taner
Journal:  World J Gastroenterol       Date:  2020-05-07       Impact factor: 5.742

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.